Zila Completes Merger With TOLMAR
19 9월 2009 - 5:00AM
Business Wire
Zila, Inc. (Nasdaq: ZILA) today announced the completion of the
merger with a subsidiary of TOLMAR Holding, Inc. Pursuant to the
merger agreement between the companies, at the effective time of
the merger all outstanding shares of Zila’s common stock were
converted into the right to receive $0.45 per share in cash.
As a result of the transaction, Zila has become a wholly owned
subsidiary of TOLMAR Holding, Inc., which also owns Tolmar, Inc., a
U.S. based privately held, pharmaceutical research, development,
manufacturing and commercial operations company. TOLMAR Holding,
Inc. expects Zila to continue as a stand alone business unit.
Effective with the close of trading today, Zila’s common stock
has ceased to be traded on the Nasdaq Market.
About TOLMAR Holding, Inc.
TOLMAR Holding, Inc. is a private pharmaceutical company.
Through its related companies it operates 5 manufacturing
facilities outside the U.S. and sells commercially branded generics
and in-licensed products in more than 20 countries.
About Zila, Inc.
Zila, Inc., headquartered in Scottsdale, Arizona, is a
diagnostic company dedicated to the prevention, detection and
treatment of oral cancer and periodontal disease. Zila manufactures
and markets ViziLite® Plus with TBlue® (“ViziLite® Plus”), the
company’s flagship product for the early detection of oral
abnormalities that could lead to cancer. ViziLite® Plus is an
adjunctive medical device cleared by the FDA for use in a
population at increased risk for oral cancer. In addition, Zila
designs, manufactures and markets a suite of proprietary products
sold exclusively and directly to dental professionals for
periodontal disease, including the Rotadent® Professional Powered
Brush, the Pro-Select Platinum® ultrasonic scaler and a portfolio
of oral pharmaceutical products for both in-office and home-care
use. All of Zila’s products are marketed and sold in the United
States and Canada primarily through the company’s direct field
sales force and telemarketing organization. The company’s products
are marketed and sold in other international markets through the
direct sales forces of third party distributors. Zila’s marketing
programs reach most U.S. dental offices.
About Tolmar, Inc.
Tolmar, Inc. is a Colorado-based pharmaceutical research,
development, manufacturing and commercial operations company.
Tolmar develops and manufacturers both proprietary and generic
pharmaceutical products with specific focus in therapeutic areas of
dental, dermatology, and oncology. The company’s strengths include
a proven developmental, clinical, regulatory and manufacturing
infrastructure with highly trained and experienced staff. Tolmar’s
lead Dental product is ATRIDOX®, which is the only Locally Applied
Antimicrobial that is clinically proven for all three of the
following indications: gain in clinical attachment, reduction in
probing depth, and reduction in bleeding on probing. Tolmar also
manufactures and sells ATRISORB® FreeFlow™ and Atrisorb®-D
FreeFlow™, which are bioabsorbable guided tissue regeneration
barriers indicated for use in periodontal surgical procedures.
For more information about Zila and its products, please visit
www.zila.com.
Zila (NASDAQ:ZILA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Zila (NASDAQ:ZILA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
